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Alzheimer’s disease (AD), the most common cause of dementia among the elderly, may either represent the
far end of a continuum that begins with age-related memory decline or a distinct pathobiological process.
Although mice that faithfully model all aspects of AD do not yet exist, current mouse models have provided
valuable insights into specific aspects of AD pathogenesis. We will argue that transgenic mice expressing
amyloid precursor protein should be considered models of accelerated brain aging or asymptomatic AD,
and the results of interventional studies in these mice should be considered in the context of primary preven-
tion. Studies in mice have pointed to the roles of soluble beta-amyloid (Ab) oligomers and soluble tau in
disease pathogenesis and support a model in which soluble Ab oligomers trigger synaptic dysfunction,
but formation of abnormal tau species leads to neuron death and cognitive decline severe enough to warrant
a dementia diagnosis.Introduction
Alzheimer’s disease (AD) is the most common cause of dementia
among the elderly. As life expectancy increases, the number of
AD cases worldwide is expected to increase from 35 million
today to more than 115 million by 2050 (http://www.alz.org/
national/documents/report_full_2009worldalzheimerreport.pdf).
The most effective approach to lessening the personal and finan-
cial costs of AD is to prevent the disease, but in order to develop
prevention strategies, it is necessary to know when and how the
disease begins. Molecular studies of the brain at the earliest
stages of memory loss associated with AD have been difficult
in humans. There is not even consensus among neurologists
and neuroscientists as to whether AD is at the far end of
a continuum that begins with age-related memory decline or
whether AD is a distinct process.
There are still no mice harboring a single Alzheimer’s-linked
gene variant that develop the progressive cognitive deficits,
plaques, tangles, and neuronal loss characteristic of the human
disease. Although there are not yet mice that faithfully model AD,
existing mouse models have provided valuable insights into
specific aspects of AD pathogenesis.
The Definition of AD Is Evolving
The nosology of AD keeps shifting, the consequence of not
knowing its etiology. This situation makes it difficult to place
mouse models precisely into human context and demands an
adaptive framework for utilizing mice as models of the human
disease.
AD Has a Long Asymptomatic Phase
Past and current criteria for a diagnosis of AD rely upon the
presence at autopsy of characteristic neuropathological
lesions, amyloid plaques formed from aggregated beta-amyloid
protein (Ab) and neurofibrillary tangles (NFTs) formed fromabnormally processed tau protein. Recent advances in imaging
technology now permit the observation of these lesions in living
subjects and confirm the findings from neuropathological
studies that up to 40% of nondemented older adults have suffi-
cient amyloid deposition to meet neuropathological criteria for
AD (Bennett et al., 2006; Hulette et al., 1998; Price et al.,
2009). The presence of substantial neuropathology in the brains
of apparently normal individuals prompted the hypothesis that
there is a long asymptomatic phase of AD, during which cogni-
tive function is largely sustained in the presence of amyloid
pathology (Price and Morris, 1999). Consistent with this hypoth-
esis, a recent longitudinal study found that elevated cortical
amyloid predicted decline in memory function (Storandt et al.,
2009) and the development of symptomatic AD (Morris et al.,
2009) in elderly adults.
Structural and functional neuroimaging studies provide further
support for the existence of a prolonged asymptomatic phase in
AD, which might precede the onset of clinical symptoms by
decades. Individuals carrying mutations associated with familial
autosomal-dominant AD are destined to develop symptoms at
a predictable age for each family; abnormal patterns of brain
activity and subtle cognitive deficits have been observed in
mutation carriers more than 25 years before their expected
conversion to dementia (Mondadori et al., 2006; Mosconi
et al., 2006). Accelerated brain atrophy appears to follow func-
tional changes, with regional differences between carriers and
noncarriers apparent5 years prior to the onset of clinical symp-
toms in the mutation carriers (Knight et al., 2009; Ridha et al.,
2006). The 34 allele of apolipoprotein E (APOE4) is the major
genetic risk factor for sporadic Alzheimer’s disease (Corder
et al., 1993), and hypometabolism in brain regions affected in
AD (de Leon et al., 1983; Kumar et al., 1991) has been observed
in young adult (Reiman et al., 2004) as well as middle-agedNeuron 66, June 10, 2010 ª2010 Elsevier Inc. 631
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Figure 1. APP and Its Major Proteolytic
Products
Cleavage of APP by a-, b-, g-, and 3-secretases
produces secreted amino-terminal fragments,
carboxyl-terminal polypeptides, and Ab. (Ma
et al., 2007; copyright 2007, National Academy of
Sciences, USA.)
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longitudinal studies, cognitively normal subjects exhibiting
regional hypometabolism during baseline examinations were
more likely to suffer future cognitive decline (de Leon et al.,
2001; Small et al., 2000) and to convert to AD (Mosconi et al.,
2008) than were subjects with normal metabolic patterns.
Volume loss in medial temporal regions in nondemented elderly
individuals increases the risk for later conversion to mild cogni-
tive impairment, considered by many to be a prodrome of AD
(Petersen and Negash, 2008), or to AD (de Toledo-Morrell
et al., 2000; den Heijer et al., 2006; Rusinek et al., 2003).
It is now possible to envision detecting AD long before the
onset of clinical symptoms. An international consortium has
attempted to identify AD at earlier stages using pathologically
relevant biochemical, imaging, genetic, and neuropsychological
tests (Dubois et al., 2007). However, the revised criteria are not
yet ready for clinical use, because the proposed new biomarkers
require further validation and are not available in most commu-
nity clinical settings (Foster, 2007a).
‘‘Pure’’ AD Is Uncommon
Complicating our ability to define AD is the observation that
amyloid plaques and NFTs coexist with other pathologies in
1/3–1/2 of patients with clinically diagnosed AD (Kovacs et al.,
2008; Schneider et al., 2009a, 2009b). Infarcts are the most
commonly occurring copathology in AD, and two theories have
been proposed to explain the observed relationships between
vascular pathology and AD: one posits an interaction between
the pathogenic factors causing the two conditions (Korczyn,
2002); the other that vascular pathology, specifically cerebral
amyloid angiopathy and the physiological effects of Ab on
blood-flow regulation, constitutes an integral pathogenic feature
of AD (Iadecola, 2004). Additional copathologies include cortical
Lewy bodies formed from aggregated a-synuclein (Schneider632 Neuron 66, June 10, 2010 ª2010 Elsevier Inc.et al., 2007, 2009a, 2009b) and TDP-
43-immunoreactive inclusions (Amador-
Ortiz et al., 2007; Higashi et al., 2007;
Josephs et al., 2008; Kadokura et al.,
2009; Uryu et al., 2008), characteristic
neuropathological lesions of Parkinson’s
disease and ALS, respectively. It is not
known whether the coexistence of these
lesions with amyloid plaques and NFTs
represents a pathological state that
promotes protein misaggregation or the
coincidental occurrence of independent
pathological processes. Regardless of
etiology, the likelihood of clinical dementia
is significantly greater in persons who have
mixed pathology than in individuals withplaques and NFTs alone (Langa et al., 2004; Schneider et al.,
2007, 2009b; Snowdon et al., 1997). There is therefore concern
that the effects of new Alzheimer therapies that are initially tested
in mouse models and humans with pure AD may differ when they
are dispensed to the general population.
Modeling AD in APP and Tau Transgenic Mice
Pioneering investigations of amyloid plaques and neurofibrillary
tangles led to the identification of the molecules comprising
these lesions, the Ab and tau proteins, respectively. Whether
or not these lesions are themselves pathogenic, their presence
reflects aberrant processing of Ab and tau that leads to protein
aggregation. Studies of the mechanisms of synapto- and neuro-
toxicity in transgenic mice have focused on toxic gains of func-
tion of these abnormal aggregates, although we cannot a priori
exclude the possibility that loss of function of normal forms of
these molecules also contributes to disease progression. Poten-
tial mechanisms of Ab- and tau-induced toxicity will be dis-
cussed in ‘‘Physiological Basis of Memory Loss in Alzheimer
Mouse Models’’ below.
Ab is generated from the proteolytic processing of the amyloid
precursor protein (APP) by b- and g-secretases (Figure 1).
Genetic studies have revealed AD-linked mutations in APP and
the presenilins, which form part of the g-secretase complex
(reviewed by Hardy, 2006). Although not found in AD, mutations
in tau are linked to another neurodegenerative disorder, fronto-
temporal dementia.
Three scientific breakthroughs made possible the creation of
the first transgenic mouse models of AD: (1) the isolation and
sequencing of the Ab peptide in 1984 (Glenner and Wong,
1984); (2) the cloning of APP and the elucidation of its role in
generating the Ab peptide (Goldgaber et al., 1987; Kang et al.,
1987; Robakis et al., 1987; Tanzi et al., 1987); and (3) the
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Reviewdiscovery of the first mutation in APP in autosomal-dominant AD
(Goate et al., 1991).
Genetic Linkage Studies Highlight APP and Tau
More than 20 autosomal-dominant APP mutations linked to AD
or cerebral amyloid angiopathy have been discovered (http://
www.molgen.ua.ac.be/ADMutations). These mutations appear
to enhance the aggregation of Ab, which occurs by one of four
mechanisms. The Swedish mutation facilitating APP cleavage
near the b-secretase site (Mullan et al., 1992) increases the over-
all production of all forms of Ab. A mutation within Ab, called the
Arctic mutation, enhances protofibril formation (Nilsberth et al.,
2001). Several mutations near the g-secretase site increase the
relative production of the more amyloidogenic Ab42 (Chartier-
Harlin et al., 1991; Goate et al., 1991; Murrell et al., 1991,
2000). Duplications of the APP gene increase production of all
forms of Ab (Rovelet-Lecrux et al., 2006; Sleegers et al., 2006).
Recently, an autosomal-recessive mutation involving the dele-
tion of glutamate at Ab residue 22 was found in a woman with
dementia who apparently lacks amyloid plaques imaged with
the amyloid binding agent Pittsburgh Compound B (Tomiyama
et al., 2008). This discovery raises the intriguing possibility that
amyloid plaques may not be required to cause AD.
Mutations in genes encoding the presenilins (80 mutations in
presenilin-1 and 10 mutations in presenilin-2) cause the re-
maining cases of early-onset familial AD (http://www.alzforum.
org/res/com/mut/pre/default.asp). Presenilin variants shift APP
cleavage at the g-secretase site, resulting in higher levels of
the more amyloidogenic Ab42 peptide.
Familial AD caused by autosomal-dominant mutations in APP
or the presenilins account for less than 10% of AD cases
(Brouwers et al., 2008; Cruts and Van Broeckhoven, 1998), while
the vast majority of cases arise sporadically. Aside from the
earlier age of onset in familial AD cases, the neuropathological
and cognitive abnormalities are generally similar in familial and
sporadic AD (Lleo´ et al., 2004; Rossor et al., 1996; Swearer
et al., 1992). The view thus has emerged that pathological pro-
cessing of APP, whether initiated by age-related factors or muta-
tions, triggers the downstream processes that mediate disease
progression (Hardy and Selkoe, 2002).
Variants of tau (40 mutations) are linked to frontotemporal
dementia (FTD), but no mutations in tau have been found in AD
families (see http://www.molgen.ua.ac.be/ADMutations/
default.cfm?MT=0&ML=1&Page=FTD for a regularly updated
list of FTD-linked mutations).
APP and Tau Transgenic Mice Are Incomplete
Models of AD
Mutations in APP or one of the presenilins are sufficient to cause
the complete AD phenotype of progressive cognitive impair-
ment, plaques, tangles, and neuron loss in the human brain.
However, when expressed in mouse brain, human transgenes
with these same mutations replicate some, but not all, aspects
of AD. APP transgenic mice develop memory loss and plaques,
with no NFTs and little or no neuron loss. Although APP trans-
genic mice fail to replicate the full human disease, they appear
to faithfully simulate the predementia phase of AD. (A few dozen
APP transgenic models have been published; a partial list can be
found online at http://www.alzforum.org/res/com/tra/app/
default.asp). Presenilin variants produce no neuropathology,but potentiate plaque deposition in APP transgenic mice.
Despite the absence of linkage to AD, transgenic mice express-
ing human tau variants have been used to study neurofibrillary
pathology, because, unlike in humans, the expression of
APP and presenilin variants in mice is insufficient to induce
neurofibrillary changes. In support of this approach, AD-related
posttranslational modifications in tau, revealed by phosphoryla-
tion- and conformation-specific monoclonal antibodies, are
promoted by FTD-linked tau mutations (Ramsden et al., 2005;
Yoshiyama et al., 2007). Duyckaerts and colleagues provide an
extensive review of the neuropathology of the most important
lines and crosses that have been generated (Duyckaerts et al.,
2008).
Several hypotheses have been put forward to explain why APP
transgenic mice do not fully recapitulate AD pathology, including
differences in neuroinflammatory responses of mice and humans
that might influence disease progression (Schwab et al., 2004;
Vitek et al., 1997; Webster et al., 1999) and differences in brain
aging between mice and humans (Loerch et al., 2008). Genetic
ablation of endogenous tau in mice expressing human tau
enhances tangle formation (Andorfer et al., 2003), suggesting
that endogenous mouse tau may interfere with the ability of
human tau to form tangles.
In addition to mice that express transgenes with disease-
linked mutations in APP, the presenilins, or tau, other models
have been developed to study specific aspects of AD pathology.
Among these are mice with targeted replacement of ApoE that
have been used to study the influence of the different human
ApoE alleles on amyloid pathology (recently reviewed by Kim
et al., 2009); transgenic mice expressing an anti-NGF antibody
that exhibit an AD-like phenotype, including cognitive deficits,
neurodegeneration, accumulation of insoluble tau, and amyloid
deposits composed of endogenous mouse Ab (Capsoni and
Cattaneo, 2006); and mice that specifically express N-terminally
truncated pyroglutamate-modified Ab3-42, a major Ab species in
AD brains (Wirths et al., 2009).
Despite that fact that there are still no mice harboring a single
Alzheimer’s-linked gene variant that develop the complete
disease phenotype, existing mouse models have provided valu-
able insights into specific aspects of AD pathogenesis.
APP Transgenic Mice Model Accelerated Aging
Two vantages have guided the interpretation of phenotypes
caused by expressing APP: an intraspecific viewpoint and an ex-
traspecific viewpoint. Studies that have used an intraspecific
reference compare phenotypes obtained in transgenic mice to
those naturally occurring in wild-type mice. Investigators that
have used an extraspecific reference focus analyses on compar-
isons between transgenic mouse phenotypes and disease
features in humans.
In humans, the assembly of Ab into one or more abnormal
species initiates a process that often, but not always, leads to
a progressive neurodegenerative condition. In mice, the process
initiated by Ab develops into a cognitive disorder that falls short
of becoming a full-blown neurodegenerative condition. Instead,
APP transgenic mice share many features with naturally aged,
nontransgenic rodents (Table 1). That the disorder resembles
natural aging distinguishes the expression of APP variants
in mice from the expression of genes linked to otherNeuron 66, June 10, 2010 ª2010 Elsevier Inc. 633
Table 1. Comparison of Memory Loss in Aging Rodents and APP Rodents
Similarities Aged Rats & Mice Citations
Transgenic APP Mice &
Ab-Infused Rats Citations
Neurological deficitsa Neophobia in aged FVB/N
mice
Hsiao et al., 1995 Neophobia in FVB/N mice
with APP transgenes
Hsiao et al., 1995
Hypometabolism in
specific brain regionsa
Hypometabolism in brain
regions linked to memory
function in aged FVB/N
mice
Hsiao et al., 1995 Hypometabolism in brain
regions linked to memory
function in FVB/N mice
with APP transgenes
Hsiao et al., 1995
Deficits in LTP likely due to
increased GABA
inhibitiona
Significantly greater
enhancement of LTP by
bicuculline in aged mice
than in young adult mice
Yoshiike et al., 2008 Significantly greater
enhancement of LTP by
bicuculline in young adult
APP/PS1 transgenic mice
than in young adult
nontransgenic mice
Yoshiike et al., 2008
In vivo LTP maintenance
impaired
Impaired maintenance,
but not induction, of
hippocampal LTP in aged
rats
Barnes, 1979 Impaired maintenance,
but not induction, of
hippocampal LTP in
transgenic mice (Tg2576,
APP/PS1) and in
Ab-infused rats
Chapman, et al., 1999;
Gureviciene et al., 2004;
Walsh et al., 2002
Hippocampal
hyperexcitability
Increased firing rates of
CA3 place cells in aged
rats
Wilson et al., 2005 Spontaneous seizure
activity in hippocampal
networks
Palop et al., 2007
Impaired Ca2+
homeostasis in neurons
Ca2+ elevated in neurons
of aged rats; Ca2+
elevated in presynaptic
terminals of aged rats;
altered sources of Ca2+
influx during induction of
LTP in aged rats; Ca2+
chelation restores LTP in
slices from aged rats but
reduces LTP in slices from
young rats and reverses
memory deficits in aged
rats
Hajieva et al., 2009;
Tonkikh et al., 2006;
Shankar et al., 1998;
Boric et al., 2008;
Reviewed in Foster, 2007b
No studies yet reported in
pre-plaque APP
transgenic mice that do
not also contain a mutant
PS1 transgene, which
itself disrupts Ca2+
dynamics
Reviewed in
Green and LaFerla, 2008;
Stutzmann, 2007
Hypothalamic-pituitary-
adrenal (HPA) stress
response defect
Impaired HPA response to
restraint-induced stress
Bizon et al., 2001 Aberrant HPA stress
response to hypoglycemia
in Tg2576 mice
Pedersen et al., 1999
Preservation of neuron
number in hippocampus
No neuronal loss in
hippocampus of aged rats
with spatial memory
deficits
Rapp and Gallagher, 1996 No neuronal loss in
hippocampus of memory-
impaired Tg2576 mice or
in aged PDAPP mice
Irizarry et al., 1997a,
1997b
Cholinergic system
changes
Shrinkage of basal
forebrain neurons
Reviewed in Finch, 1993 Cholinergic terminal
reorganization in Tg2576 X
PS1 mice; basal forebrain
neuron shrinkage in
TgAPP mice with London
mutation
Wong et al., 1999;
Bronfman et al., 2000
Oxidative stress markers
increased
Increased signatures of
oxidative stress in aged
rats with spatial memory
deficits
Nicolle et al., 2001 Increased oxidative stress
markers in aged Tg2576
mice
Smith et al., 1998;
Pappolla et al., 1999;
Pratico` et al., 2001
Caloric deprivation Caloric deprivation
prevents memory loss
in rats
Pitsikas and Algeri, 1992 Caloric restriction
decreases amyloid
deposition in APP and
APP/PS1 mice; preserves
spatial memory in Tg2576
mice
Patel et al., 2005;
Mouton et al., 2009;
Qin et al., 2008
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Table 1. Continued
Similarities Aged Rats & Mice Citations
Transgenic APP Mice &
Ab-Infused Rats Citations
Beneficial effects of COX
inhibition
Nimesulide (COX-2
inhibitor) attenuates
memory deficits in aged
mice; NSAIDs (nimesulide,
rofecoxib, naproxen)
reverse memory deficits in
aged mice, no effect in
young mice
Bishnoi et al., 2005;
Jain et al., 2002
NSAIDs prevent
(ibuprofen) or reverse
(ibuprofen, naproxen,
MF-tricyclic) memory
deficits in Tg2576 mice,
no effect in non-tg
Kotilinek et al. (2008)
PKC-gamma elevation Increased in aged rats
with spatial memory
deficits
Colombo et al., 1997;
Colombo and Gallagher,
2002
Increased in aged Tg2576
mice
Rossner et al., 2001
Environmental enrichment Environmental enrichment
improves memory
performance in aged but
not young male mice;
exercise improves
memory in younger female
mice, but exercise +
cognitive enrichment
needed to improve
memory in older female
mice
Harburger et al., 2007a,
2007b
Exercise, social
interactions, and cognitive
enrichment improve
cognitive function in APP
and APP/PS1 transgenic
mice but also improve
cognitive function in
nontransgenic controls
Costa et al., 2007;
Jankowsky et al., 2005
Brain Ab elevation Murine Ab rises with age
in mice
Fukumoto et al., 2004 Human Ab rises with age
in APP transgenic mice
Games et al., 1995;
Hsiao et al. (1996);
Sturchler-Pierrat et al.,
1997; Chishti et al., 2001
Differences Aged Rats & Mice Citations Transgenic APP Mice
and Ab-Infused Rats
Citations
Amyloid deposits None (rodent Ab) Present (human Ab)
AMPA binding in
hippocampus
No change in aged rats;
no relationship to memory
Nicolle et al., 1996 Increased in aged Tg2576
mice
Cha et al., 2001
NMDA binding in
hippocampus
Decreased in aged rats;
inverse relationship to
memory
Nicolle et al., 1996;
Adams et al., 2001
No change in aged
Tg2576 mice
Cha et al., 2001
Effect of SOD2
overexpression
SOD2 overexpression
has no effect on
age-associated memory
impairment or LTP
Hu et al., 2007 SOD2 overexpression
prevents memory
impairments in Tg19959
mice
Dumont et al., 2009
a Studies that directly compared phenotypes of transgenic mice and age-matched and older nontransgenic mice of the same background strain.
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amyotrophic lateral sclerosis, prion diseases, and Huntington’s
disease, and may provide a tantalizing clue about why AD is
the most common neurodegenerative condition in man.
Studies using the intraspecific approach support the idea that
natural aging and aberrant APP metabolism may be inextricably
linked. A comprehensive study in the FVB/N mouse strain exem-
plifies this approach (Hsiao et al., 1995). In20% of FVB/N mice
>150 days of age, a neurological syndrome develops that is
characterized by neophobia, cerebral astrogliosis without
amyloid plaques, and diminished cerebral glucose utilization in
the hippocampus, amygdala, entorhinal cortex, temporal cortex,
and parietal cortex (association neocortex), but not in the
somatosensory, frontal, or occipital cortices (primary neocortex).
The regional brain glucose hypo-utilization occurs in regionsassociated with learning, memory, and affective behavior and
overlaps strikingly with brain regions that are affected in people
with AD or at risk for AD (Figure 2). The expression of human APP
in mice accelerates this syndrome in a dose-dependent fashion.
Importantly, no amyloid plaques form in the impaired mice, sug-
gesting that the APP metabolite(s) responsible for initiating brain
dysfunction are soluble Ab species that are generated prior to
amyloid deposition.
The prediction that aberrant APP metabolism will accelerate
age-related neural dysfunction was borne out in studies of
senescence-accelerated prone mice (SAMP), which were
derived from a parent strain of AKR/J mice (Takeda et al.,
1981). Fourteen substrains of SAMP mice have been generated
(Takeda, 1999), five of which develop deficits in learning and
memory within the first year. One of these substrains, SAMP8,Neuron 66, June 10, 2010 ª2010 Elsevier Inc. 635
Figure 2. Regional Hypometabolism in APP
Transgenic Mice and People at Risk for AD
MRI and [18F]-FDG-PET scans of (A) a control
subject and (B) a carrier of a presenilin-1 mutation
associated with familial autosomal-dominant AD,
27 years before mean age of onset of dementia
in her family. Bilateral hypometabolism of parietal
cortex and medial temporal lobe is evident on
PET in the absence of atrophy on MRI. (C)
Regional cerebral glucose utilization, monitored
with [14C]2-deoxyglucose, in the cortex and
hippocampus of a neophobic transgenic FVB/N
mouse expressing human APP with a disease-
linked mutation. Compared to its nontransgenic
littermate, the transgenic mouse shows de-
creases in glucose utilization in cerebral cortex and hippocampus. Pseudocolored images of autoradiograms of coronal sections through cerebral cortex, hippo-
campus, and anterior brainstem; warmer colors represent greater glucose uptake. (D) Magnified view of (C) showing hippocampus and overlying cerebral cortex.
(A and B) Reprinted by permission of the Society of Nuclear Medicine from Mosconi et al. (2006). (C and D) Reprinted with permission from Elsevier from Hsiao
et al. (1995).
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Figure 3. APP Transgenic Mice Model Asymptomatic Alzheimer’s
Disease
APP transgenic mice exhibit functional abnormalities similar to those observed
in people at risk for Alzheimer’s disease but do not display the loss of neurons
seen in people clinically diagnosed with mild cognitive impairment or
Alzheimer’s disease.
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(Okuma and Nomura, 1998). The cognitive deficits in SAMP8
mice improve following administration of Ab antibodies or anti-
sense oligonucleotides that lower APP mRNA, indicating a role
for the aberrant metabolism of mouse APP and the overproduc-
tion of mouse Ab (Banks et al., 2001; Kumar et al., 2000; Morley
et al., 2000). No amyloid plaques form in SAMP8 mice. These
studies in AKR/J mice confirm the finding in FVB/N mice that
abnormal APP metabolism can accelerate naturally occurring
age-related brain disorders, independently of amyloid plaque
deposition.
The conclusion that aberrant APP processing accelerates
age-related neural dysfunction was drawn from studies using
an intraspecific frame of reference, comparing the phenotypes
of transgenic or selectively inbred mice to the parent strain.
Using an extraspecific frame of reference, comparing patterns
of brain hypometabolism observed in APP transgenic mice
(Hsiao et al., 1995) with those observed in humans with AD or
at risk for AD (de Leon et al., 2007; Mosconi et al., 2008; Petrie
et al., 2009), we suggest that APP transgenic mice model asymp-
tomatic AD (Figure 3). The factors that cause the transition from
asymptomatic AD to full-blown AD are unknown, and there are
not yet transgenic mouse models suitable for addressing this
question.
Initiation versus Mediation of Cognitive Dysfunction
In mice, the amount and type of Ab generated govern the forma-
tion of amyloid plaques. Amyloid plaques will form in the cere-
brum within the first year of life when Ab levels exceed
a threshold, which is 30 pmoles/gm Ab40 and 10 pmoles/
gm Ab42 (Hsiao et al., 1996). Modifier genes that reduce Ab40
and Ab42 below this threshold by only 20% cause a near
doubling of the time to amyloid deposition (Lehman et al.,
2003), and further reductions in Ab levels preclude amyloid
plaque formation altogether. Increasing the ratio of Ab42:Ab40
or introducing mutations into Ab that increase its propensity to
aggregate lowers the threshold required for plaques to form
(Cheng et al., 2004; Mucke et al., 2000). Neurofibrillary tangles
form in the brains of mice expressing either wild-type or mutant
human tau. Neurofibrillary tangles form in cortical neurons of
mice by 18 months of age when wild-type tau expression occurs
at 5-fold that of endogenous mouse tau (Ishihara et al., 2001).636 Neuron 66, June 10, 2010 ª2010 Elsevier Inc.In general, mutant tau induces neurofibrillary tangle formation at
lower levels than wild-type tau, and tangles develop earlier, often
within the first year of life. The effective levels for generating
tangles of mutant tau range from 0.7-fold to 5-fold endoge-
nous mouse tau levels (Go¨tz et al., 2001a; Schindowski et al.,
2006; Yoshiyama et al., 2007).
Within a given APP or tau transgenic line, different mice
succumb at different ages, even when the mice are inbred, indi-
cating that environmental or stochastic processes, about which
we know nothing, interact with the transgenic proteins to induce
disease. Once disease has begun, all mice in plaque- and tangle-
bearing APP and tau transgenic lines will eventually develop
these neuropathological lesions. However, APP and tau trans-
genic mice differ in the proportion of mice that develop behav-
ioral abnormalities. Not all APP transgenic mice become
impaired; a small number of very old APP transgenic mice will
possess abundant plaques but minimal cognitive deficits (West-
erman et al., 2002), reminiscent of cognitively intact humans with
abundant plaques at death (Schneider et al., 2007). In contrast,
all tau mice that exhibit neuropathology eventually develop
neurological deficits.
In APP transgenic mice, the incomplete penetrance of the
neurological deficits contrasts with the complete penetrance
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Figure 4. Ab Initiates a Disease Process
that Might Progress to a Stage of Cognitive
Impairment, but Tau Mediates Cognitive
Dysfunction
In this hypothetical scheme, Ab*56 (see ‘‘Soluble
Ab Oligomers Are Associated with Memory Defi-
cits in APP Transgenic Mice’’) and perhaps other
Ab oligomers cause synaptic dysfunction that
manifests as subtle cognitive deficits in APP trans-
genic mice and in people in the asymptomatic
phase of AD. Toxic Ab oligomers surrounding pla-
ques locally damage neurons, but their effects on
cognition are unknown (see ‘‘Plaque-Associated
Abnormalities’’). Abnormal tau processing trig-
gered by pathological forms of Ab in AD, and by
mutations in tau transgenic mice, causes loss of
synapses and neurons and cognitive deficits
severe enough to warrant a diagnosis of mild
cognitive impairment (MCI) or AD. The effects of
NFTs, rather than soluble pathological forms of
tau, are unknown (see ‘‘Targets of Ab’’). It is also
not known whether the same effector molecules/
mechanisms responsible for Ab-induced synaptic
and cognitive dysfunction trigger tau abnormali-
ties or whether a separate pathway is involved.
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stream or parallel to the generation of observable lesions,
present in some but not all mice, must be engaged to impair
cognitive function. Conversely, as yet unknown compensatory
mechanisms might exist that protect some, but not all, mice
from suffering cognitive decline. Compensatory mechanisms
appear unable to protect tau transgenic mice from brain
dysfunction, however. These observations are consistent with
the hypothesis that Ab initiates a disease process that might
progress to a stage of cognitive impairment, but that tau
mediates cognitive dysfunction (Figure 4). Several lines of
evidence from transgenic mice and observations of human
pathology support this hypothesis.
Studies in mice from at least four independent laboratories
have shown that Ab can potentiate tau pathology (Bolmont
et al., 2007; Go¨tz et al., 2001b; Lewis et al., 2001; Oddo et al.,
2004), consistent with the hypothesis that tau abnormalities
develop downstream of Ab in AD. An increase in NFTs was
observed in the brains of transgenic mice expressing human
tauP301L, a tau variant linked to frontotemporal dementia, when
these mice were crossed with mice expressing human APP
with a mutation linked to familial AD (Lewis et al., 2001). Intrace-
rebral injection of fibrillar synthetic Ab42 (Go¨tz et al., 2001b) or
brain lysates from APP transgenic mice (Bolmont et al., 2007)
induced a significant increase in the numbers of NFTs in the
brains of transgenic mice that express human tauP301L. In the
3xTg-AD mouse, which expresses disease-linked variants of
APP, presenilin-1, and tau (Oddo, et al., 2003), subtle memoryNeurondeficits presenting prior to tau pathology
give way to severe deficits that are
accompanied by tau abnormalities (Bill-
ings et al., 2005). The reduction of soluble
Ab and tau, but not soluble Ab alone,
abrogated the severe deficits (Oddo
et al., 2006). Thus, it appears that patho-logically altered tau is a major factor in late-stage cognitive
deficits.
Physiological Basis of Memory Loss in Alzheimer
Mouse Models
Memory loss in AD historically was explained by the disruption of
neuronal architecture, connectivity, and viability due to the
accumulation of NFTs and amyloid plaques. However, while
studies in humans have thus far focused on the correlation
between neuropathological lesions and cognitive decline, recent
studies in transgenic mice suggest that attention also should be
paid to soluble species of Ab and tau that appear before amyloid
plaques and NFTs and cause synaptic dysfunction and neurode-
generation.
Soluble Ab Oligomers Are Associated with Memory
Deficits in APP Transgenic Mice
In elderly individuals, amyloid burden, considered independently
of NFTs, is a poor predictor of cognitive function (Bennett et al.,
2004; Giannakopoulos et al., 2003; Grober et al., 1999). Similarly,
APP and APP/PS1 transgenic mice exhibit a range of correla-
tions between memory dysfunction and plaques (Gordon et al.,
2001; Holcomb et al., 1999; Westerman et al., 2002). The incon-
sistent relationship between plaque load and degree of cognitive
impairment led to the hypothesis that soluble oligomeric forms of
Ab are the pathogenic species in AD (Westerman et al., 2002).
Lesne´ et al. (2006) isolated from the brains of APP transgenic
mice a specific Ab oligomer, Ab*56, that correlates with impaired
memory in these mice and induces memory dysfunction when66, June 10, 2010 ª2010 Elsevier Inc. 637
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dip in the levels of Ab*56 coincides with an interlude of normal
memory function occurring at a time when the rate, not the
amount, of amyloid deposition peaks (Lesne´ et al., 2008). Cheng
et al. (Cheng et al., 2007) compared memory function in plaque-
forming APP transgenic mice possessing Ab*56 to plaque-form-
ing mice lacking Ab*56 and found deficits only in the mice with
Ab*56.
Plaque-Associated Abnormalities
The studies of Cheng et al. and Lesne´ et al. indicate that when
the plaque load is modest (<1% of the cross-sectional area of
brain sections), Ab*56 appears to be the cause of memory
dysfunction, but do not address whether abundant amyloid
plaques contribute to cognitive decline. There is plentiful
evidence that the microenvironment surrounding amyloid
plaques is toxic to neurons. Neurons immediately adjacent
(within 10 mm of the edge of the fibrillar Ab) to plaques die
(Urbanc et al., 2002), and those located within an 50 mm halo
exhibit altered electrophysiological properties (Busche et al.,
2008; Stern et al., 2004), distorted neurites (Knowles et al.,
1999; Meyer-Luehmann et al., 2008), and loss of dendritic spines
(Spires-Jones et al., 2007; Spires et al., 2005) and excitatory
synapses (Koffie et al., 2009). Passive immunotherapy with
monoclonal antibodies directed against Ab decreases the
number of dystrophic neurites without altering plaque burden
(Rozkalne et al., 2009), suggesting that soluble Ab in the vicinity
of plaques mediates the effects on neurite architecture. Interest-
ingly, antibodies directed against oligomeric Ab stain profiles
within and surrounding plaques; although it cannot be certain
that the locations of these profiles in fixed tissue precisely
reflects their locations in vivo, excitatory postsynaptic densities
that colocalize with these profiles are40% smaller than normal
(Koffie et al., 2009). Notwithstanding the robust neuronal abnor-
malities associated with plaques, their contribution to memory
and cognitive deficits remains unknown.
The contributions to cognitive dysfunction of specific Ab olig-
omers and fibrillar Ab deposited in plaques are clinically signifi-
cant, as this will determine the success of new methods for
reducing and imaging plaque load in affecting and monitoring
the neurological status of Alzheimer patients. The relevance of
Ab*56 to human disease has yet to be established, although syn-
aptotoxic Ab dimers have been isolated from AD brains (Shankar
et al., 2008). Finally, the issue has been raised as to whether
particular Ab oligomers exist in vivo or whether they are created
artifactually during the extraction process. Pending the develop-
ment of oligomer-specific reagents capable of detecting their
targets in vivo, this will remain a question for debate.
Neurophysiological Abnormalities in APP Transgenic
Mice
Studies in APP transgenic mice, which exhibit cognitive deficits
in the absence of neurodegeneration, have led to the conclusion
that AD begins as a disease of synaptic dysfunction. Given that
hippocampal long-term potentiation (LTP) arguably represents
an electrophysiological correlate of learning and memory (Martin
et al., 2000), several laboratories have attempted to determine
whether APP transgenic mice exhibit deficits in hippocampal
LTP. Unfortunately, a consistent story has not emerged from
these studies, with results ranging from deficits in LTP to638 Neuron 66, June 10, 2010 ª2010 Elsevier Inc.enhanced LTP (summarized in Table S1). These discrepancies
might be explained by several factors, including transgene,
background strain, age, anesthetic state of mice in studies
in vivo, health of in vitro preparations, and the precise stimulus
protocols used to evoke LTP.
It is quite possible that APP transgenic mice undergo more
complex changes in activity-dependent plasticity or metaplas-
ticity than those revealed in conventional studies of LTP. Electro-
physiological studies in APP transgenic mice appear to have
fallen out of favor, probably due to the discouraging lack of
consistency in existing studies. Correlative behavioral, electro-
physiological, and biochemical studies of mice at different
ages within single lines are needed to determine how abnormal
Ab species impact the function of specific neural circuits.
Based on their immunohistochemical and electrophysiological
findings, Mucke and colleagues have put forth the intriguing
suggestion that hyperexcitability within the hippocampus trig-
gers a compensatory remodeling of inhibitory circuits, either or
both of which could contribute to deficits in hippocampal-based
memory tasks (Palop et al., 2007). In support of this hypothesis,
nonepileptic doses of the GABAA antagonist picrotoxin rescued
cognitive deficits in mice expressing transgenes for both mutant
human APP and mutant human PS1 (Yoshiike et al., 2008).
Cognitive deficits in APP transgenic mice can be rapidly
reversed by passive immunization with monoclonal antibodies
directed against Ab (Dodart et al., 2002; Kotilinek et al., 2002).
If immunization as rapidly reverses the remodeling of inhibitory
circuits, this would provide further support for the hypothesis
of Mucke and Palop; otherwise, it is more likely that Ab-induced
memory dysfunction in these mice is due to acute effects of Ab at
synapses.
If the hippocampus is indeed hyperexcitable in APP transgenic
mice, these mice might be expected to have an increased
susceptibility to epileptic seizures compared to nontransgenic
mice of the same age and background. Lower seizure thresholds
or more severe seizures in response to excitotoxic challenge (Del
Vecchio et al., 2004; Jolas et al., 2002; Palop et al., 2007;
Westmark et al., 2008) and spontaneous behavioral or electro-
graphic seizures (Chin et al., 2007; Minkeviciene et al., 2009;
Palop et al., 2007) have been reported in several lines. Epilepsy
does occur more commonly among the elderly with AD than in
cognitively intact individuals (recently reviewed by Palop and
Mucke, [2009]), suggesting that the relevance of seizure suscep-
tibility to the mechanism of memory dysfunction in AD deserves
further study.
Targets of Ab
The molecular targets of specific, naturally derived Ab oligomers
are largely unknown, although their interactions with particular
pathways have been inferred from physiological, biochemical,
and pharmacological studies. Table S2 lists the several recep-
tors and processes shown to be affected by various Ab species.
As mentioned above, the determination of which Ab species are
actually important in disrupting memory function in vivo awaits
the development of reagents that target specific Ab oligomers.
The intracellular effector molecules and pathways modulated
by Ab are also largely unknown, although P21-activated kinases
(Ma et al., 2008; Zhao et al., 2006), the Src family tyrosine kinase
Fyn (Chin et al., 2005; Lambert et al., 1998), protein phosphatase
Neuron
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cyclooxygenase-2 (Kotilinek et al., 2008), cAMP (Shrestha et al.,
2006), and phospholipase A2 (Sanchez-Mejia et al., 2008) have
all been implicated in Ab-induced synaptic deficits and cognitive
dysfunction. In addition to the neurodegenerative changes
thought to underlie the clinical phase of AD, tau might also
mediate the more subtle synaptic and cognitive deficits induced
by Ab (Roberson et al., 2007).
Do Soluble Tau Species Mediate Cognitive Dysfunction/
Neuronal Damage?
When transgenic tau is suppressed in mice expressing a regulat-
able tau transgene (rTg4510 mice), NFTs continue to accumu-
late, but neuron loss is arrested (Santacruz et al., 2005; Spires
et al., 2006) and memory function recovers (Santacruz et al.,
2005). This dissociation between neurofibrillary pathology and
neuron death is supported by observations that neuron loss far
exceeds NFT number in AD brains (Go´mez-Isla et al., 1997)
and dying neurons in the brains of tau transgenic mice frequently
do not contain NFTs (Andorfer et al., 2005; Spires et al., 2006).
These observations led to the hypothesis that an as yet unknown
posttranslationally modified form of the tau protein, and not
NFTs, is responsible for cognitive dysfunction and neuron loss.
It has been reported that a 170 kDa tau multimer correlates
with memory dysfunction in rTg4510 mice and with the appear-
ance of motor deficits in JNPL3 tau transgenic mice that express
tauP301L in the spinal cord and that 170-kDa tau is found in
brains of FTD and AD patients (Berger et al., 2007), but deter-
mining whether this species causes memory dysfunction will
be challenging.
While much of the study of tau-induced pathology has focused
on neuron loss, tau-induced synaptic dysfunction might also
have a role in memory impairment. In transgenic mice expressing
tauP301S, decreases in the presynaptic markers synaptophysin
and a-synuclein become apparent at 3 months of age, and
synaptic dysfunction is well advanced by the time NFTs appear
at 6 months (Yoshiyama et al., 2007), suggesting the involvement
of soluble tau. Additional studies have demonstrated synaptic
dysfunction in transgenic tau mice, but these studies did not
address whether functional deficits precede the appearance of
NFTs (Rosenmann et al., 2008; Schindowski et al., 2006).
The mechanisms through which tau kills neurons or impairs
synaptic function remain unknown. It has been suggested that
impaired axon transport might prevent the anterograde delivery
of necessary cellular components, including mitochondria, from
the soma to the axon terminal or retrograde delivery of
neurotrophic factors from postsynaptic targets to the nucleus
(Mandelkow et al., 2003; Stoothoff et al., 2009).
Physiological Roles of APP Metabolites and Tau
The majority of studies in transgenic mice have focused on toxic
gains of function of abnormally processed APP and tau.
However, it is also possible that loss of function of normal forms
of these molecules or their metabolites contributes to disease
progression.
APP moves via fast anterograde axonal transport from central
and peripheral neuronal cell bodies to nerve terminals (Buxbaum
et al., 1998; Koo et al., 1990). In nerve terminals, APP undergoes
proteolysis at a-, b-, g-, and 3-secretase sites to release amino-
terminal, internal, and carboxyl-terminal polypeptides, includingAPP intracellular domain (AICD), Ab, and secreted APPa
(sAPPa). Because APP trafficking and cleavage can be regulated
by neuronal activity (Cirrito et al., 2005; Kamenetz et al., 2003;
Tampellini et al., 2009), a physiological role for APP and its
cleavage products has been proposed. The observation that
genetic ablation of APP impairs memory is consistent with this
idea (Dawson et al., 1999; Senechal et al., 2007; Senechal
et al., 2008). sAPPa enhances memory when injected into the
cerebral ventricles of mice (Meziane et al., 1998), and AICD
has been suggested to improve memory in transgenic mice
(Laird et al., 2005; Ma et al., 2007). Cleavage of APP might also
have a role in axon pruning during development; trophic factor
deprivation stimulates b-secretase-dependent cleavage of an
N-terminal fragment of APP, which binds to death receptor-6
and triggers axon degeneration (Nikolaev et al., 2009). The
production of sAPPa via a-secretase cleavage of APP and of
AICD and Ab via the b- and g-secretase pathways are mutually
exclusive. Further studies are required to understand the types
of neural processes that regulate and are in turn regulated by
these two pathways.
Tau binds and promotes the assembly of tubulin (Weingarten
et al., 1975) and is essential for normal neuronal maturation in
culture and microtubule organization in mice (Dawson et al.,
2001; Harada et al., 1994). Biochemical methods detect tau in
all neuronal compartments, but immunohistochemistry shows
it primarily in axons, where tau is enriched in axonal microtu-
bules. Studies addressing the role of tau in the brain suggest
involvement in development, learning, and plasticity. The over-
expression of tau improved memory and long-lasting synaptic
plasticity, before the onset of tau hyperphosphorylation and
tauopathy (Boekhoorn et al., 2006). Its absence produced hyper-
activity and impaired fear-conditioning in one tau knockout line
(Ikegami et al., 2000), but not in another (Roberson et al.,
2007). No explanation for the discrepancy between phenotypes
in the two tau knockout lines has been offered. Genetic ablation
of tau in adult mice, by conditional knockout or siRNA methods,
has not been reported but may reveal additional functions of tau
in the brain.
Overall Conclusions
Despite being incomplete disease models, transgenic mice have
provided important insights into the pathobiology of AD. Studies
using the intraspecific approach have demonstrated that
abnormal APP metabolism can accelerate naturally occurring
age-related brain disorders, independently of amyloid plaque
deposition. These results blur the distinction between age-
related cognitive decline and asymptomatic AD. Further studies
in mice have pointed to the roles of soluble Ab oligomers and
soluble tau in disease pathogenesis and support a model in
which (1) soluble Ab oligomers trigger synaptic dysfunction; (2)
subsequently, Ab oligomers shed from plaques might contribute
to additional synaptic dysfunction but at this point, in humans,
the disease is still presymptomatic; (3) formation of abnormal
tau species leads to neuron death and cognitive decline severe
enough to warrant a dementia diagnosis. The identity of soluble
toxic tau species has yet to be confirmed, but several lines of
evidence in mice lead to the conclusion that NFTs themselves
are not required for neuron death or dysfunction.Neuron 66, June 10, 2010 ª2010 Elsevier Inc. 639
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ReviewResearchers urgently need more-complete mouse models of
AD, although it is far from clear how to achieve these. The ability
of Ab to induce NFTs comprised of wild-type human tau has
never been demonstrated in transgenic mice. Since tau muta-
tions are not required for NFT formation in AD, this failure of
current mouse models seriously compromises our ability to
study the nexus of interactions between Ab and tau in AD and
also generates potentially misleading results in mice used for
preclinical testing of AD therapies. At present, APP transgenic
mice should be considered models of accelerated brain aging
or asymptomatic AD, and the results of interventional studies
in these mice should be considered in the context of primary
prevention.
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